GioTag: Real-world Data Study on Sequential Therapy With Gi(l)Otrif/ Afatinib as First-line Treatment Followed by Osimertinib in Patients With EGFR Mutation Positive Advanced Non-small Cell Lung Cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Afatinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GioTag
- Sponsors Boehringer Ingelheim
- 02 Sep 2020 According to a Boehringer Ingelheim media release, conclusions from this study were published in in Future Oncology.
- 02 Sep 2020 According to a Boehringer Ingelheim media release, Dr. Maximilian J. Hochmair is the coordinating investigator of this study.
- 02 Sep 2020 Results of final analysis published in the Boehringer Ingelheim Media Release